Literature DB >> 2007857

The major histocompatibility complex class II-linked cim locus controls the kinetics of intracellular transport of a classical class I molecule.

S J Powis1, J C Howard, G W Butcher.   

Abstract

The dominant trans-acting major histocompatibility complex (MHC)-linked class I modifier (cim) locus, previously recognized through its ability to determine altered alloantigenicity of a rat class I molecule, RT1.A3, is shown here to influence class I intracellular transport. The MHC recombinant laboratory rat strains PVG.R1 and PVG.R8 display unusually long retention of RT1.Aa within the endoplasmic reticulum or cis-Golgi. In appropriate F1 hybrid cells heterozygous for RT1.Aa and another class I MHC allele, RT1.Ac, only the RT1.Aa protein is subject to slow transport. The cim gene product therefore shows class I allele specificity in its action, cim appears to be a polymorphic locus whose product is directly involved in the processes of class I MHC assembly and/or intracellular transport.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007857      PMCID: PMC2190796          DOI: 10.1084/jem.173.4.913

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  30 in total

1.  Identification of classical minor histocompatibility antigen as cell-derived peptide.

Authors:  H J Wallny; H G Rammensee
Journal:  Nature       Date:  1990-01-18       Impact factor: 49.962

Review 2.  Evolution of class-I MHC genes and proteins: from natural selection to thymic selection.

Authors:  D A Lawlor; J Zemmour; P D Ennis; P Parham
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

3.  Presentation of viral antigen controlled by a gene in the major histocompatibility complex.

Authors:  V Cerundolo; J Alexander; K Anderson; C Lamb; P Cresswell; A McMichael; F Gotch; A Townsend
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

Review 4.  Polypeptide chain binding proteins: catalysts of protein folding and related processes in cells.

Authors:  J E Rothman
Journal:  Cell       Date:  1989-11-17       Impact factor: 41.582

5.  Defective presentation of endogenous antigen by a cell line expressing class I molecules.

Authors:  N A Hosken; M J Bevan
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

6.  The transport of class I major histocompatibility complex antigens is determined by sequences in the alpha 1 and alpha 2 protein domains.

Authors:  J Alexander; J A Payne; B Shigekawa; J A Frelinger; P Cresswell
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

7.  Concerted evolution of class I genes in the major histocompatibility complex of murine rodents.

Authors:  C Rada; R Lorenzi; S J Powis; J van den Bogaerde; P Parham; J C Howard
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

8.  Differential transport requirements of HLA and H-2 class I glycoproteins.

Authors:  J Alexander; J A Payne; R Murray; J A Frelinger; P Cresswell
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

9.  Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

10.  A trans-acting major histocompatibility complex-linked gene whose alleles determine gain and loss changes in the antigenic structure of a classical class I molecule.

Authors:  A M Livingstone; S J Powis; A G Diamond; G W Butcher; J C Howard
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  14 in total

1.  Different rates of HLA class I molecule assembly which are determined by amino acid sequence in the alpha 2 domain.

Authors:  A Hill; M Takiguchi; A McMichael
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

Review 2.  Restrictions on the use of antigenic peptides by the immune system.

Authors:  J C Howard
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

3.  Alloreactive cytotoxic T-lymphocyte-defined HLA-B7 subtypes differ in peptide antigen presentation.

Authors:  K D Smith; D F Epperson; C T Lutz
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

Review 4.  Regulation of ABC transporter function via phosphorylation by protein kinases.

Authors:  Elzbieta I Stolarczyk; Cassandra J Reiling; Christian M Paumi
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

5.  Polymorphic peptide transporters in MHC class I monomorphic Syrian hamster.

Authors:  M Lobigs; H S Rothenfluh; R V Blanden; A Müllbacher
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  The distribution of Tap2 alleles among laboratory rat RT1 haplotypes.

Authors:  E Joly; E V Deverson; J W Coadwell; E Günther; J C Howard; G W Butcher
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

7.  Recognition of vaccinia virus-encoded major histocompatibility complex class I antigens by virus immune cytotoxic T cells is independent of the polymorphism of the peptide transporters.

Authors:  M Lobigs; A Müllbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

8.  Cim: an MHC class II-linked allelism affecting the antigenicity of a classical class I molecule for T lymphocytes.

Authors:  A M Livingstone; S J Powis; E Günther; D V Cramer; J C Howard; G W Butcher
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

Review 9.  HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-07       Impact factor: 2.332

10.  Genetic modulation of antigen presentation by HLA-B27 molecules.

Authors:  L Pazmany; S Rowland-Jones; S Huet; A Hill; J Sutton; R Murray; J Brooks; A McMichael
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.